FDA Approves Cabometyx for pNET and epNET

The FDA granted approval for cabozantinib (Cabometyx, Exelixis) for adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumor (pNET) and well-differentiated extra-pancreatic neuroendocrine tumor (epNET).

Efficacy of cabozantinib for patients with NET was evaluated in CABINET (ClinicalTrials.gov. Identifier: NCT03375320), a multicenter, double-blind, placebo-controlled trial